Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial - PubM
8 days ago
- #Chemotherapy
- #Bladder Cancer
- #Radiotherapy
- The study compared radiotherapy with twice-weekly Gemcitabine and Cisplatin versus Cisplatin alone for organ preservation in muscle-invasive bladder cancer (MIBC).
- Primary endpoint was 2-year disease-free survival (DFS), with no significant difference found between the two treatment groups.
- Overall survival (OS) rates at 24 and 60 months were reported, showing varied results between the treatment arms.
- Toxicity profiles were similar between groups, except for increased cytopenias in the Gemcitabine arm.
- The addition of Gemcitabine to Cisplatin did not improve 2-year DFS in MIBC patients undergoing trimodal therapy (TMT).
- Study limitations included early termination and insufficient patient accrual, suggesting cautious interpretation of results.